

Robert P Giugliano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9149405/publications.pdf>

Version: 2024-02-01

456
papers

45,046
citations

3721

89
h-index

2171

202
g-index

464
all docs

464
docs citations

464
times ranked

28516
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104. | 13.9 | 4,215 |
| 2 | Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722. | 13.9 | 4,179 |
| 3 | Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2014, 383, 955-962. | 6.3 | 3,942 |
| 4 | Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 372, 2387-2397. | 13.9 | 3,337 |
| 5 | Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1500-1509. | 13.9 | 1,352 |
| 6 | TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation. <i>Circulation</i> , 2000, 102, 2031-2037. | 1.6 | 1,302 |
| 7 | Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1289. | 3.8 | 974 |
| 8 | Abciximab Facilitates the Rate and Extent of Thrombolysis. <i>Circulation</i> , 1999, 99, 2720-2732. | 1.6 | 661 |
| 9 | Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes. <i>Circulation</i> , 2005, 111, 2042-2049. | 1.6 | 613 |
| 10 | Variation in <i>PCSK9</i> and <i>HMGCR</i> and Risk of Cardiovascular Disease and Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 2144-2153. | 13.9 | 596 |
| 11 | Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350. | 1.6 | 559 |
| 12 | Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019, 139, 1483-1492. | 1.6 | 533 |
| 13 | Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. <i>Lancet, The</i> , 2017, 390, 1962-1971. | 6.3 | 487 |
| 14 | Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 360, 2176-2190. | 13.9 | 459 |
| 15 | Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017, 5, 941-950. | 5.5 | 452 |
| 16 | Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillationâ€“Thrombolysis In Myocardial Infarction study 48 (ENGAGE AFâ€“TIMI 48). <i>American Heart Journal</i> , 2010, 160, 635-641.e2. | 1.2 | 439 |
| 17 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. <i>Lancet, The</i> , 2012, 380, 2007-2017. | 6.3 | 379 |
| 18 | Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017, 377, 633-643. | 13.9 | 366 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2288-2295. | 6.3 | 335 |
| 20 | Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). <i>Journal of the American College of Cardiology</i> , 2014, 63, 1278-1288. | 1.2 | 316 |
| 21 | TNKâ€™Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction. <i>Circulation</i> , 1998, 98, 2805-2814. | 1.6 | 307 |
| 22 | Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1571-1582. | 1.6 | 304 |
| 23 | The P-Glycoprotein Transport System and Cardiovascular Drugs. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2495-2502. | 1.2 | 297 |
| 24 | Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0 0 rgBT /Overlock 10 T outcomes in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2008, 156, 826-832. | 1.2 | 280 |
| 25 | Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2005, 352, 1646-1654. | 13.9 | 278 |
| 26 | Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2000, 101, 239-243. | 1.6 | 267 |
| 27 | Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. <i>Circulation</i> , 2015, 132, 1224-1233. | 1.6 | 267 |
| 28 | Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. <i>Journal of the American College of Cardiology</i> , 2003, 42, 1535-1543. | 1.2 | 247 |
| 29 | A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. <i>Lancet, The</i> , 2001, 358, 1571-1575. | 6.3 | 245 |
| 30 | Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016, 134, 24-36. | 1.6 | 234 |
| 31 | A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. <i>Journal of Clinical Lipidology</i> , 2016, 10, 472-489. | 0.6 | 219 |
| 32 | Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AFâ€™TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, . | 1.6 | 215 |
| 33 | St-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. <i>American Journal of Cardiology</i> , 2000, 85, 299-304. | 0.7 | 212 |
| 34 | Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia. <i>Circulation</i> , 2014, 129, 234-243. | 1.6 | 204 |
| 35 | Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 756-766. | 1.6 | 200 |
| 36 | Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , 2018, 138, 131-140. | 1.6 | 194 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. <i>Journal of Lipid Research</i> , 2016, 57, 1086-1096. | 2.0 | 180 |
| 38 | Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <i>European Heart Journal</i> , 2014, 35, 1457-1465. | 1.0 | 174 |
| 39 | Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016, 67, 353-361. | 1.2 | 173 |
| 40 | Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes. <i>Circulation</i> , 2019, 140, 1308-1317. | 1.6 | 172 |
| 41 | Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2888-2899. | 1.2 | 171 |
| 42 | Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 109, 580-586. | 1.6 | 169 |
| 43 | Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2020, 396, 1637-1643. | 6.3 | 167 |
| 44 | Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality. <i>Circulation</i> , 2011, 123, 2681-2689. | 1.6 | 164 |
| 45 | AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy. <i>Circulation</i> , 2013, 128, 962-969. | 1.6 | 161 |
| 46 | Meta-analysis of corticosteroid treatment in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 91, 1055-1059. | 0.7 | 160 |
| 47 | Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. <i>Journal of the American College of Cardiology</i> , 2003, 42, 7-16. | 1.2 | 160 |
| 48 | Rationale and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. <i>American Heart Journal</i> , 2016, 173, 94-101. | 1.2 | 158 |
| 49 | Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. <i>JAMA Cardiology</i> , 2018, 3, 823. | 3.0 | 158 |
| 50 | Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921. | 1.2 | 157 |
| 51 | Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2638-2651. | 1.2 | 156 |
| 52 | Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2280-2287. | 6.3 | 153 |
| 53 | U-Shaped Relationship of Blood Glucose With Adverse Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 178-180. | 1.2 | 152 |
| 54 | Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. <i>JAMA Cardiology</i> , 2017, 2, 547. | 3.0 | 144 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score. <i>Circulation</i> , 2020, 141, 616-623. | 1.6 | 143 |
| 56 | Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, . | 2.1 | 139 |
| 57 | Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2002, 40, 71-77. | 1.2 | 138 |
| 58 | Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1999, 34, 974-982. | 1.2 | 137 |
| 59 | Long-term Low-Density Lipoprotein Cholesterol—Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia. <i>JAMA Cardiology</i> , 2017, 2, 598. | 3.0 | 137 |
| 60 | Novel biomarkers in cardiovascular disease: Update 2010. <i>American Heart Journal</i> , 2010, 160, 583-594. | 1.2 | 136 |
| 61 | Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1169-1178. | 1.2 | 133 |
| 62 | Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275. | 1.6 | 133 |
| 63 | Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2012, 107, 925-934. | 1.8 | 132 |
| 64 | Updates on Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 718. | 3.0 | 127 |
| 65 | Oral Anticoagulation in Patients With Liver Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2162-2175. | 1.2 | 127 |
| 66 | Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. <i>European Heart Journal</i> , 2004, 25, 1998-2005. | 1.0 | 124 |
| 67 | Acute coronary syndromes. <i>Lancet</i> , 2022, 399, 1347-1358. | 6.3 | 122 |
| 68 | Anticoagulation Strategies in Patients With Cancer. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1336-1349. | 1.2 | 121 |
| 69 | A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1879-1885. | 1.2 | 119 |
| 70 | Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 1069. | 3.0 | 119 |
| 71 | Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255. | 1.6 | 118 |
| 72 | Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. <i>European Heart Journal</i> , 2014, 35, 2249-2259. | 1.0 | 115 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2961-2970. | 1.2 | 115 |
| 74 | Thiazolidinedione Drugs and Cardiovascular Risks. <i>Circulation</i> , 2010, 121, 1868-1877. | 1.6 | 113 |
| 75 | Elderly Patients Receive Less Aggressive Medical and Invasive Management of Unstable Angina. <i>Archives of Internal Medicine</i> , 1998, 158, 1113. | 4.3 | 112 |
| 76 | EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2016, 37, 1296.1-1303. | 1.0 | 112 |
| 77 | Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382. | 1.2 | 111 |
| 78 | Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. <i>JAMA Cardiology</i> , 2022, 7, 250. | 3.0 | 108 |
| 79 | Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e008987. | 1.6 | 105 |
| 80 | Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. <i>JAMA Cardiology</i> , 2018, 3, 749. | 3.0 | 105 |
| 81 | REDUCE-IT USA. <i>Circulation</i> , 2020, 141, 367-375. | 1.6 | 104 |
| 82 | Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1363-1371. | 1.2 | 102 |
| 83 | Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Trial. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1486-1494. | 1.7 | 102 |
| 84 | Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. <i>Stroke</i> , 2020, 51, 1546-1554. | 1.0 | 102 |
| 85 | Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2132-2146. | 1.2 | 101 |
| 86 | Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019, 139, 760-771. | 1.6 | 99 |
| 87 | Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <i>Circulation</i> , 2016, 134, 248-261. | 1.6 | 98 |
| 88 | Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 934-943. | 5.5 | 96 |
| 89 | Combination reperfusion therapy with eptifibatid and reduced-dose tenecteplase for ST-elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1251-1260. | 1.2 | 93 |
| 90 | Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1. | 1.2 | 93 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, . | 1.6 | 93 |
| 92 | Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. <i>American Heart Journal</i> , 2002, 144, 1003-1011. | 1.2 | 92 |
| 93 | Practical Management of Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1340-1360. | 1.2 | 92 |
| 94 | Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin. <i>JAMA Cardiology</i> , 2017, 2, 1385. | 3.0 | 89 |
| 95 | Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1541-1550. | 1.0 | 88 |
| 96 | Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2013, 165, 918-925.e2. | 1.2 | 87 |
| 97 | The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY Tj ETQq1 1 0.784314 rgBT front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—Study design and rationale. <i>American Heart Journal</i> , 2005, 149, 994-1002. | 1.2 | 85 |
| 98 | Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 331. | 3.8 | 84 |
| 99 | Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082. | 1.0 | 83 |
| 100 | Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation—An ENGAGE AF-TIMI 48 Subanalysis. <i>Circulation</i> , 2016, 80, 860-869. | 0.7 | 83 |
| 101 | An update on the IMPROVED Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. <i>American Heart Journal</i> , 2010, 159, 705-709. | 1.2 | 82 |
| 102 | Lipoprotein(a) and its Significance in Cardiovascular Disease. <i>JAMA Cardiology</i> , 2022, 7, 760. | 3.0 | 82 |
| 103 | Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4A simple index that predicts mortality in ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 783-789. | 1.2 | 81 |
| 104 | Thiazolidinedione Drugs and Cardiovascular Risks. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1885-1894. | 1.2 | 81 |
| 105 | Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. <i>JAMA Cardiology</i> , 2019, 4, 846. | 3.0 | 81 |
| 106 | Angiographic and Clinical Outcomes Among Patients With Acute Coronary Syndromes Presenting With Isolated Anterior ST-Segment Depression. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 806-811. | 1.1 | 79 |
| 107 | Comparison of long-term mortality across the spectrum of acute coronary syndromes. <i>American Heart Journal</i> , 2006, 151, 1065-1071. | 1.2 | 77 |
| 108 | Digoxin: Clinical Highlights. <i>Critical Pathways in Cardiology</i> , 2011, 10, 93-98. | 0.2 | 77 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Selecting the Best Reperfusion Strategy in ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2003, 108, 2828-2830. | 1.6 | 76 |
| 110 | Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non-“ST-Segment” Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2012, 126, 41-49. | 1.6 | 74 |
| 111 | Prognostic Performance of a High-Sensitivity Cardiac Troponin I Assay in Patients with Non-“ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2014, 60, 158-164. | 1.5 | 74 |
| 112 | High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction. <i>Circulation</i> , 2000, 101, 2690-2695. | 1.6 | 73 |
| 113 | Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from <scp>ENGAGE AF-TIMI</scp> 48. <i>European Journal of Heart Failure</i> , 2016, 18, 1153-1161. | 2.9 | 73 |
| 114 | Recombinant Nematode Anticoagulant Protein c2 in Patients With Non-“ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2398-2407. | 1.2 | 72 |
| 115 | Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2012, 165, 500-514. | 1.2 | 72 |
| 116 | Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. <i>American Heart Journal</i> , 2004, 148, 336-340. | 1.2 | 71 |
| 117 | The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. <i>European Heart Journal</i> , 2016, 37, 3576-3584. | 1.0 | 71 |
| 118 | Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. <i>American Heart Journal</i> , 2001, 141, 742-750. | 1.2 | 69 |
| 119 | Determinants of coronary blood flow after thrombolytic administration. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1403-1412. | 1.2 | 67 |
| 120 | Novel Oral Anticoagulants in Atrial Fibrillation: A Meta-analysis of Large, Randomized, Controlled Trials vs Warfarin. <i>Clinical Cardiology</i> , 2013, 36, 61-67. | 0.7 | 67 |
| 121 | Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019, 40, 1518-1527. | 1.0 | 67 |
| 122 | Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 613. | 3.0 | 66 |
| 123 | Implications of Upstream Glycoprotein IIb/IIIa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/Non-“ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 109, 874-880. | 1.6 | 65 |
| 124 | Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. <i>Journal of the American College of Cardiology</i> , 2008, 52, 914-920. | 1.2 | 64 |
| 125 | Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 999. | 3.0 | 64 |
| 126 | An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020, 5, 709. | 3.0 | 63 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Cognition After Lowering LDL-Cholesterol With Evolocumab. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2283-2293. | 1.2 | 62 |
| 128 | The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , 2020, 141, 1600-1607. | 1.6 | 61 |
| 129 | The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 48, 37-42. | 1.2 | 60 |
| 130 | Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79â€¦808 patients. <i>Heart</i> , 2014, 100, 396-405. | 1.2 | 58 |
| 131 | Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 870-880. | 1.9 | 58 |
| 132 | Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <i>American Journal of Medicine</i> , 2016, 129, 850-857.e2. | 0.6 | 58 |
| 133 | Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 37-45. | 0.4 | 57 |
| 134 | LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 805-812. | 0.8 | 57 |
| 135 | Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 952. | 3.0 | 56 |
| 136 | Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants. <i>JAMA Cardiology</i> , 2017, 2, 442. | 3.0 | 55 |
| 137 | Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy. A cognitive study of patients enrolled in the FOURIER trial. <i>Clinical Cardiology</i> , 2017, 40, 59-65. | 0.7 | 54 |
| 138 | Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3013-3022. | 1.2 | 54 |
| 139 | Antithrombotics in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 969-984. | 1.2 | 53 |
| 140 | Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, . | 1.6 | 53 |
| 141 | Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Clinical Cardiology</i> , 2016, 39, 345-346. | 0.7 | 53 |
| 142 | Electrocardiographic and Clinical Predictors of Acute Myocardial Infarction in Patients With Unstable Angina Pectoris 11Dr. Camargo was supported by grant HL-03533 and Dr. Giugliano was supported by grant HL-07575 from the National Institutes of Health, Bethesda, Maryland.. <i>American Journal of Cardiology</i> , 1998, 81, 1182-1186. | 0.7 | 51 |
| 143 | The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , 2018, 270, 245-252. | 0.8 | 51 |
| 144 | Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 0.7 | 50 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 110, 679-684. | 1.6 | 50 |
| 146 | AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Programâ€Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 430-433. | 1.2 | 50 |
| 147 | Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. <i>JAMA Cardiology</i> , 2021, 6, 139. | 3.0 | 50 |
| 148 | Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. <i>American Journal of Cardiology</i> , 2004, 93, 1362-1367. | 0.7 | 49 |
| 149 | Neural Network Assessment of Perioperative Cardiac Risk in Vascular Surgery Patients. <i>Medical Decision Making</i> , 1998, 18, 70-75. | 1.2 | 48 |
| 150 | Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. <i>American Journal of Cardiology</i> , 2000, 86, 1235-1237. | 0.7 | 48 |
| 151 | Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. <i>American Journal of Cardiology</i> , 2001, 88, 353-358. | 0.7 | 48 |
| 152 | Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4. <i>Journal of the American College of Cardiology</i> , 2004, 44, 783-789. | 1.2 | 48 |
| 153 | Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationâ€. <i>European Heart Journal</i> , 2015, 36, 1470-1477. | 1.0 | 47 |
| 154 | Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. <i>Stroke</i> , 2014, 45, 2372-2378. | 1.0 | 46 |
| 155 | Reduction in Revascularization With Icosapent Ethyl. <i>Circulation</i> , 2021, 143, 33-44. | 1.6 | 46 |
| 156 | Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019, 40, 1492-1500. | 1.0 | 45 |
| 157 | Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab. <i>JAMA Cardiology</i> , 2019, 4, 59. | 3.0 | 45 |
| 158 | Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019, 21, 1571-1579. | 2.9 | 44 |
| 159 | Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 980-987. | 1.2 | 43 |
| 160 | Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVEâ€IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Journal of the American Heart Association</i> , 2017, 6, . | 1.6 | 43 |
| 161 | Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6277-6286. | 0.8 | 43 |
| 162 | Distance from the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial Infarction and its Implications Regarding the Potential Prevention of Proximal Plaque Rupture. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 15, 189-196. | 1.0 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population. <i>Clinical Cardiology</i> , 2017, 40, 155-162. | 0.7 | 41 |
| 164 | Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non-ST-Elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 93, 1218-1222. | 0.7 | 40 |
| 165 | The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 906-919. | 1.2 | 40 |
| 166 | Prior Aspirin Use and Outcomes in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1376-1385. | 1.2 | 39 |
| 167 | Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatid Treatment in Patients With Acute Coronary Syndrome. <i>Circulation</i> , 2011, 123, 722-730. | 1.6 | 39 |
| 168 | Regional Patterns of Use of a Medical Management Strategy for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 205-213. | 0.9 | 39 |
| 169 | Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non-ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends. <i>Journal of the American College of Cardiology</i> , 2013, 62, 242-251. | 1.2 | 39 |
| 170 | Transition of Patients From Blinded Study-Drug to Open-Label Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 576-584. | 1.2 | 39 |
| 171 | Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021, 144, 1845-1855. | 1.6 | 39 |
| 172 | Association of Unstable Angina Guideline Care With Improved Survival. <i>Archives of Internal Medicine</i> , 2000, 160, 1775. | 4.3 | 37 |
| 173 | Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy. <i>Clinical Cardiology</i> , 2012, 35, 385-391. | 0.7 | 37 |
| 174 | A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw565. | 1.0 | 37 |
| 175 | Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1660-1671. | 1.2 | 36 |
| 176 | Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010, 31, 2103-2110. | 1.0 | 35 |
| 177 | Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin: Insights From the ENGAGE AF-TIMI 48 Trial. <i>Circulation Journal</i> , 2015, 79, 2560-2567. | 0.7 | 35 |
| 178 | Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 179-189. | 1.2 | 35 |
| 179 | Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. <i>Ageing Research Reviews</i> , 2019, 49, 115-124. | 5.0 | 34 |
| 180 | Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 448-458. | 0.9 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | Gastrointestinal Bleeding With Edoxaban Versus Warfarin. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003998. | 0.9 | 33 |
| 182 | Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 1406-1410. | 0.7 | 32 |
| 183 | Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018, 138, 1963-1973. | 1.6 | 32 |
| 184 | Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1057-1068. | 1.2 | 32 |
| 185 | Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478. | 1.6 | 32 |
| 186 | Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 92, 1155-1159. | 0.7 | 31 |
| 187 | Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2004, 25, 1702-1710. | 1.0 | 31 |
| 188 | Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (A Meta-Analysis of a Decade of Trials). <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 119-129. | 1.0 | 31 |
| 189 | Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. <i>American Heart Journal</i> , 2009, 157, 673-679.e1. | 1.2 | 31 |
| 190 | The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2010, 56, 2126-2138. | 1.2 | 31 |
| 191 | Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2296-2304. | 1.2 | 31 |
| 192 | Evolocumab in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 785-788. | 13.9 | 31 |
| 193 | Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 321-323. | 1.2 | 30 |
| 194 | Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 357-367. | 0.9 | 30 |
| 195 | Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, . | 1.6 | 30 |
| 196 | Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves. <i>Circulation</i> , 2018, 138, 1356-1365. | 1.6 | 30 |
| 197 | A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 175-180. | 1.0 | 29 |
| 198 | Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. <i>American Heart Journal</i> , 2002, 143, 966-970. | 1.2 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 537-544. | 1.2 | 29 |
| 200 | Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. <i>Journal of the American College of Cardiology</i> , 2020, 75, 289-300. | 1.2 | 29 |
| 201 | Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1197-1207. | 1.2 | 29 |
| 202 | Modes and timing of death in 66,252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018, 39, 3810-3820. | 1.0 | 28 |
| 203 | Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021, 42, 1698-1706. | 1.0 | 27 |
| 204 | Effects of tirofiban plus heparin versus heparin alone on troponin i levels in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2000, 86, 713-717. | 0.7 | 26 |
| 205 | First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. <i>American Heart Journal</i> , 2000, 140, 81-92. | 1.2 | 26 |
| 206 | Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. <i>American Heart Journal</i> , 2000, 140, 373-378. | 1.2 | 26 |
| 207 | Association of Epicardial and Tissue-Level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 17, 177-184. | 1.0 | 26 |
| 208 | Improved speed and stability of st-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 549-556. | 1.2 | 26 |
| 209 | Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. <i>American Heart Journal</i> , 2004, 147, 847-852. | 1.2 | 26 |
| 210 | Association of a History of Systemic Hypertension With Mortality, Thrombotic, and Bleeding Complications Following Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of Clinical Hypertension</i> , 2006, 8, 315-322. | 1.0 | 26 |
| 211 | Impact of Time of Presentation on Process Performance and Outcomes in ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 656-663. | 0.9 | 26 |
| 212 | Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. <i>American Heart Journal</i> , 2015, 170, 1140-1150. | 1.2 | 26 |
| 213 | Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. <i>Journal of the American Heart Association</i> , 2022, 11, e022937. | 1.6 | 26 |
| 214 | Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239,234 Patients During 2005 to 2018 in the United States. <i>Journal of the American Heart Association</i> , 2022, 11, e022198. | 1.6 | 26 |
| 215 | Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). <i>American Journal of Cardiology</i> , 2005, 95, 611-614. | 0.7 | 25 |
| 216 | Niacin at 56 Years of Age – Time for an Early Retirement?. <i>New England Journal of Medicine</i> , 2011, 365, 2318-2320. | 13.9 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Achievement of Guideline-Concordant Care and In-Hospital Outcomes in Patients With Coronary Artery Disease in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 58-65. | 0.9 | 25 |
| 218 | Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. <i>Heart Rhythm</i> , 2016, 13, 2340-2347. | 0.3 | 25 |
| 219 | Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 856-864. | 1.1 | 25 |
| 220 | Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2020, 304, 185-191. | 0.8 | 25 |
| 221 | Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1525-1537. | 1.2 | 25 |
| 222 | Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors? , 1998, 5, 191-202. | | 24 |
| 223 | North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29. | 0.6 | 24 |
| 224 | Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 77, 259-267. | 1.2 | 24 |
| 225 | Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041. | 0.9 | 23 |
| 226 | Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction. <i>JAMA Cardiology</i> , 2020, 5, 787. | 3.0 | 23 |
| 227 | Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , 2021, 42, 4821-4829. | 1.0 | 23 |
| 228 | Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). <i>American Journal of Cardiology</i> , 2000, 85, 1409-1413. | 0.7 | 22 |
| 229 | Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: Insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. <i>American Heart Journal</i> , 2013, 166, 723-728. | 1.2 | 22 |
| 230 | Edoxaban. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 409-416. | 1.0 | 22 |
| 231 | Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. <i>JAMA Cardiology</i> , 2017, 2, 556. | 3.0 | 22 |
| 232 | Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2019, 140, 1792-1801. | 1.6 | 22 |
| 233 | Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 140-149. | 1.8 | 22 |
| 234 | Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695. | 1.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1499-1507. | 1.2 | 22 |
| 236 | Heart-Type Fatty Acid Binding Protein as a marker of reperfusion after thrombolytic therapy. <i>Clinica Chimica Acta</i> , 2000, 298, 85-97. | 0.5 | 21 |
| 237 | The Prognostic Value of Serum Creatinine on Admission in Fibrinolytic-Eligible Patients with Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 167-174. | 1.0 | 21 |
| 238 | Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 92, 595-597. | 0.7 | 21 |
| 239 | Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 383-386. | 0.7 | 21 |
| 240 | Effect of Thrombocytopenia on Outcomes Following Treatment With Either Enoxaparin or Unfractionated Heparin in Patients Presenting With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2007, 100, 1734-1738. | 0.7 | 21 |
| 241 | Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, . | 1.6 | 21 |
| 242 | The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. <i>European Heart Journal</i> , 2004, 25, 1139-1145. | 1.0 | 20 |
| 243 | Usefulness of the TIMI Risk Index in Predicting Short- and Long-Term Mortality in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2005, 96, 773-777. | 0.7 | 20 |
| 244 | The facts behind niacin. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 227-240. | 1.0 | 20 |
| 245 | Relation Between Time of Symptom Onset of <scp>ST</scp>â€œSegment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. <i>Clinical Cardiology</i> , 2013, 36, 222-227. | 0.7 | 20 |
| 246 | Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 97-106. | 1.4 | 19 |
| 247 | Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. <i>American Heart Journal</i> , 2015, 170, 669-674. | 1.2 | 19 |
| 248 | First experience with edoxaban and atrial fibrillation ablation â€œ Insights from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2017, 244, 192-195. | 0.8 | 19 |
| 249 | Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 927-935. | 1.1 | 18 |
| 250 | Can We Predict Outcomes in Atrial Fibrillation?. <i>Clinical Cardiology</i> , 2012, 35, 10-4. | 0.7 | 18 |
| 251 | Radial versus femoral access, bleeding and ischemic events in patients with nonâ€œST-segment elevation acute coronary syndrome managed with an invasive strategy. <i>American Heart Journal</i> , 2013, 165, 583-590.e1. | 1.2 | 18 |
| 252 | Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013, 168, 2510-2517. | 0.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 253 | Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 111-127. | 1.0 | 18 |
| 254 | Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017, 377, 1996-1997. | 13.9 | 18 |
| 255 | Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2018, 257, 102-107. | 0.8 | 18 |
| 256 | Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1001-1008. | 1.8 | 18 |
| 257 | Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 176-185. | 0.4 | 18 |
| 258 | Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy). <i>American Journal of Cardiology</i> , 2003, 92, 598-600. | 0.7 | 17 |
| 259 | Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016, 133, 1560-1573. | 1.6 | 17 |
| 260 | Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era. <i>JAMA Cardiology</i> , 2017, 2, 935. | 3.0 | 17 |
| 261 | Andexanet Alfa (Andexxa) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2019, 18, 66-71. | 0.2 | 17 |
| 262 | Prognostic value of SPECT myocardial perfusion imaging in patients with elevated cardiac troponin I levels and atypical clinical presentation. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 53-58. | 1.4 | 16 |
| 263 | Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. <i>Future Cardiology</i> , 2011, 7, 459-470. | 0.5 | 16 |
| 264 | Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. <i>International Journal of Cardiology</i> , 2013, 167, 2580-2587. | 0.8 | 16 |
| 265 | New oral anticoagulants in patients with atrial fibrillation – Authors' reply. <i>Lancet, The</i> , 2014, 384, 25-26. | 6.3 | 16 |
| 266 | Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , 2019, 74, 597-605. | 1.3 | 16 |
| 267 | Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. <i>American Journal of Cardiology</i> , 2020, 127, 176-183. | 0.7 | 16 |
| 268 | What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. <i>Cardiology and Therapy</i> , 2020, 9, 59-73. | 1.1 | 16 |
| 269 | Characteristics and prognosis of patients with suspected acute myocardial infarction and elevated MB relative index but normal total creatine kinase. <i>American Journal of Cardiology</i> , 1999, 84, 957-962. | 0.7 | 15 |
| 270 | Prognostic Implications of Low Level Cardiac Troponin Elevation Using High-Sensitivity Cardiac Troponin T. <i>Clinical Cardiology</i> , 2015, 38, 230-235. | 0.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | A novel approach indirectly comparing benefitâ€“risk balance across anti-thrombotic therapies in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 15-28. | 1.4 | 15 |
| 272 | On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). <i>American Heart Journal</i> , 2016, 182, 89-96. | 1.2 | 15 |
| 273 | 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 114-115. | 3.3 | 14 |
| 274 | Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. <i>Chronobiology International</i> , 2012, 29, 1390-1396. | 0.9 | 14 |
| 275 | Association of metabolic syndrome and its individual components with outcomes among patients with high-risk nonâ€“ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2014, 168, 182-188.e1. | 1.2 | 14 |
| 276 | The Year in Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 201-214. | 1.2 | 14 |
| 277 | Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3425-3435. | 1.1 | 14 |
| 278 | Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, 1117-1123.e2. | 0.6 | 14 |
| 279 | Competing Risks of Cardiovascular Versus Noncardiovascular Death During Longâ€“Term Followâ€“Up After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, . | 1.6 | 14 |
| 280 | Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. <i>Circulation</i> , 2021, 144, 1732-1734. | 1.6 | 14 |
| 281 | Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. <i>Journal of the American College of Cardiology</i> , 2005, 45, 357-362. | 1.2 | 13 |
| 282 | Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. <i>American Heart Journal</i> , 2009, 158, 695-705. | 1.2 | 13 |
| 283 | Lipid lowering goals: back to nature?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 185-191. | 1.0 | 13 |
| 284 | The Year in Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2127-2139. | 1.2 | 13 |
| 285 | The relationship between meteorological conditions and index acute coronary events in a global clinical trial. <i>International Journal of Cardiology</i> , 2013, 168, 2315-2321. | 0.8 | 13 |
| 286 | Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 555-559. | 1.0 | 13 |
| 287 | Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience. <i>Cardiology and Therapy</i> , 2015, 4, 197-201. | 1.1 | 13 |
| 288 | Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillationâ€“Thrombolysis in Myocardial Infarction 48 (ENGAGE AFâ€“TIMI 48) trial. <i>American Heart Journal</i> , 2016, 172, 144-151. | 1.2 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 554-561. | 0.4 | 13 |
| 290 | Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58,634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f40-f49. | 1.4 | 13 |
| 291 | Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects—A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. <i>Circulation Journal</i> , 2021, 85, 2063-2070. | 0.7 | 13 |
| 292 | Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina. <i>American Heart Journal</i> , 2000, 139, 867-873. | 1.2 | 12 |
| 293 | Combination Reperfusion Therapy with Eptifibatide and Tenecteplase for Acute Myocardial Infarction. <i>Cardiology</i> , 2001, 1, 5-13. | 0.3 | 12 |
| 294 | Anticoagulation After Heart Valve Replacement or Transcatheter Valve Implantation. <i>American Journal of Cardiology</i> , 2016, 118, 1419-1426. | 0.7 | 12 |
| 295 | Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 167-175. | 1.4 | 12 |
| 296 | Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. <i>American Journal of Cardiology</i> , 2004, 94, 178-181. | 0.7 | 11 |
| 297 | Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: Insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. <i>Canadian Journal of Cardiology</i> , 2009, 25, e417-e421. | 0.8 | 11 |
| 298 | Dabigatran. <i>Critical Pathways in Cardiology</i> , 2011, 10, 117-127. | 0.2 | 11 |
| 299 | In Patients With Acute Myocardial Infarction, the Impact of Hyperglycemia as a Risk Factor for Mortality Is Not Homogeneous Across Age-Groups. <i>Diabetes Care</i> , 2012, 35, 150-152. | 4.3 | 11 |
| 300 | High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32. | 1.2 | 11 |
| 301 | Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. <i>Value in Health Regional Issues</i> , 2017, 12, 74-83. | 0.5 | 11 |
| 302 | Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58. | 1.2 | 11 |
| 303 | Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. <i>International Journal of Cardiology</i> , 2012, 155, 424-429. | 0.8 | 10 |
| 304 | Bridging therapy after recent stent implantation: case report and review of data. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 30-38. | 0.3 | 10 |
| 305 | Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. <i>International Journal of Cardiology</i> , 2013, 167, 548-554. | 0.8 | 10 |
| 306 | Angiographic Outcomes With Early Eptifibatide Therapy in Non-ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial). <i>American Journal of Cardiology</i> , 2014, 113, 1297-1305. | 0.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1466-1475. | 1.2 | 10 |
| 308 | Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 423-432. | 1.0 | 10 |
| 309 | Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Tj ETQq1 1 0.784314 rgBT /Overlo Outcomes, 2020, 6, 284-292. | 1.8 | 10 |
| 310 | Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021, 143, 673-684. | 1.6 | 10 |
| 311 | Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011382. | 1.4 | 10 |
| 312 | The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1095-1103. | 1.2 | 9 |
| 313 | One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. <i>European Heart Journal</i> , 2010, 31, 2097-2102. | 1.0 | 9 |
| 314 | Coronary Artery Stents: Advances in Technology. <i>Hospital Practice (1995)</i> , 2014, 42, 83-91. | 0.5 | 9 |
| 315 | Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1019-1034. | 0.9 | 9 |
| 316 | DOACs in Patients With Mitral Stenosis and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1132-1134. | 1.2 | 9 |
| 317 | Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens. <i>Drugs</i> , 2009, 69, 1433-1443. | 4.9 | 8 |
| 318 | Dabigatran Excess: Case Report and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 111-124. | 1.1 | 8 |
| 319 | Acute Dissection of the Descending Aorta: A Case Report and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 199-213. | 1.1 | 8 |
| 320 | Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology. <i>European Heart Journal</i> , 2013, 34, 2031-2033. | 1.0 | 8 |
| 321 | Genotype-Guided Dosing of Warfarin. <i>Clinical Chemistry</i> , 2014, 60, 920-922. | 1.5 | 8 |
| 322 | Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). <i>American Journal of Cardiology</i> , 2016, 118, 625-631. | 0.7 | 8 |
| 323 | Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017, 130, 1170-1176. | 0.6 | 8 |
| 324 | Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, . | 0.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 325 | Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 591-598. | 0.8 | 8 |
| 326 | Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. <i>European Heart Journal Digital Health</i> , 2022, 3, 38-48. | 0.7 | 8 |
| 327 | Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 6, 103-108. | 1.0 | 7 |
| 328 | Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 1113-1117. | 0.7 | 7 |
| 329 | A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the EXTRACT-TIMI 25 ECG study. <i>European Heart Journal</i> , 2007, 28, 2070-2076. | 1.0 | 7 |
| 330 | The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2342-2354. | 1.2 | 7 |
| 331 | Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. <i>American Heart Journal</i> , 2011, 162, 884-892.e1. | 1.2 | 7 |
| 332 | Effectiveness and Safety of Percutaneous Coronary Intervention After Fibrinolytic Therapy for ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2011, 107, 1001-1009. | 0.7 | 7 |
| 333 | Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. <i>International Journal of Cardiology</i> , 2017, 232, 264-270. | 0.8 | 7 |
| 334 | Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials. <i>Heart Rhythm</i> , 2017, 14, 599-605. | 0.3 | 7 |
| 335 | PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2018, 12, 835-843. | 0.6 | 7 |
| 336 | The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 435-442. | 1.3 | 7 |
| 337 | Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. <i>JACC: CardioOncology</i> , 2020, 2, 385-396. | 1.7 | 7 |
| 338 | Management of LDL cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. <i>Clinical Cardiology</i> , 2020, 43, 684-690. | 0.7 | 7 |
| 339 | Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. <i>Circulation</i> , 2021, 144, 249-251. | 1.6 | 7 |
| 340 | Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. <i>Current Opinion in Lipidology</i> , 2022, 33, 147-159. | 1.2 | 7 |
| 341 | A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 49-52. | 1.0 | 6 |
| 342 | Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1170-1176. | 1.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 343 | Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2010, 159, 55-62. | 1.2 | 6 |
| 344 | Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 217-224. | 1.0 | 6 |
| 345 | Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. <i>Europace</i> , 2019, 21, 306-312. | 0.7 | 6 |
| 346 | Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006511. | 0.9 | 6 |
| 347 | Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006. | 1.6 | 6 |
| 348 | Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. <i>American Heart Journal</i> , 2022, 247, 24-32. | 1.2 | 6 |
| 349 | Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. <i>European Heart Journal Supplements</i> , 2022, 24, A1-A10. | 0.0 | 6 |
| 350 | Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 108-111. | 0.7 | 5 |
| 351 | Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. <i>American Journal of Cardiology</i> , 2005, 95, 337-342. | 0.7 | 5 |
| 352 | The Year in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2006, 48, 386-395. | 1.2 | 5 |
| 353 | When Past Is Prologue. <i>New England Journal of Medicine</i> , 2009, 360, 1016-1022. | 13.9 | 5 |
| 354 | The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1544-1555. | 1.2 | 5 |
| 355 | Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTEMI) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTEMI (EARLY) trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 934-942. | 0.7 | 5 |
| 356 | Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. <i>International Journal of Cardiology</i> , 2016, 222, 615-619. | 0.8 | 5 |
| 357 | Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. <i>International Journal of Cardiology</i> , 2016, 203, 708-713. | 0.8 | 5 |
| 358 | Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. <i>JAMA Cardiology</i> , 2021, 6, 582. | 3.0 | 5 |
| 359 | Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 294-300. | 0.8 | 5 |
| 360 | Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 695-706. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. <i>PLoS ONE</i> , 2022, 17, e0266615. | 1.1 | 5 |
| 362 | Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: do the results apply to all patients?. <i>American Journal of Cardiology</i> , 2000, 86, 908-912. | 0.7 | 4 |
| 363 | Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2689-2694. | 1.9 | 4 |
| 364 | Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 228-233. | 0.7 | 4 |
| 365 | The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2008, 131, 105-112. | 0.8 | 4 |
| 366 | Management of ST-Elevation Myocardial Infarction. <i>American Journal of Cardiovascular Drugs</i> , 2008, 8, 187-197. | 1.0 | 4 |
| 367 | Antiplatelet Therapy in Early Management of Non-ST-segment Elevation Acute Coronary Syndrome: The 2002 and 2007 Guidelines From North America and Europe. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 425-433. | 0.8 | 4 |
| 368 | ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 1-10. | 1.0 | 4 |
| 369 | Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. <i>Journal of Interventional Cardiology</i> , 2011, 24, 119-136. | 0.5 | 4 |
| 370 | Clinical Implications and Correlates of Q Waves in Patients With <sc>ST</sc>â€Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the <sc>CLARITYâ€TIMI</sc> 28 Trial. <i>Clinical Cardiology</i> , 2014, 37, 160-166. | 0.7 | 4 |
| 371 | Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. <i>Current Opinion in Cardiology</i> , 2016, 31, 644-653. | 0.8 | 4 |
| 372 | Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 857-864. | 0.7 | 4 |
| 373 | Cardiovascular Events and Longâ€Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVEâ€T. <i>Journal of the American Heart Association</i> , 2022, 11, e022733. | 1.6 | 4 |
| 374 | Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. <i>Journal of Clinical Lipidology</i> , 2022, 16, 538-543. | 0.6 | 4 |
| 375 | Low-Molecular-Weight Heparins for the Treatment of Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 391-402. | 2.1 | 3 |
| 376 | Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond. <i>Future Cardiology</i> , 2007, 3, 365-375. | 0.5 | 3 |
| 377 | The Year in Nonâ€ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1386-1395. | 1.2 | 3 |
| 378 | Antiplatelet Therapy in Percutaneous Coronary Intervention. <i>Critical Pathways in Cardiology</i> , 2009, 8, 12-19. | 0.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 379 | Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. <i>Current Atherosclerosis Reports</i> , 2013, 15, 290. | 2.0 | 3 |
| 380 | Cholesterol Levels and the Association of Statins With In-Hospital Mortality of Myocardial Infarction Patients Insights From a Chilean Registry of Myocardial Infarction. <i>Clinical Cardiology</i> , 2013, 36, 305-311. | 0.7 | 3 |
| 381 | Perioperative Management of Target-Specific Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2014, 42, 38-45. | 0.5 | 3 |
| 382 | Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Hospital Practice (1995)</i> , 2015, 43, 258-267. | 0.5 | 3 |
| 383 | Reply. <i>Journal of the American College of Cardiology</i> , 2016, 68, 326. | 1.2 | 3 |
| 384 | Major Bleeding in Patients With Diabetes and Atrial Fibrillation Treated With New Oral Anticoagulants—Reply. <i>JAMA Cardiology</i> , 2017, 2, 1168. | 3.0 | 3 |
| 385 | Impact of Antithrombotic Regimen on Mortality, Ischemic, and Bleeding Outcomes after Transcatheter Aortic Valve Replacement. <i>Cardiology and Therapy</i> , 2018, 7, 71-77. | 1.1 | 3 |
| 386 | Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. <i>Cardiology and Therapy</i> , 2020, 9, 1-4. | 1.1 | 3 |
| 387 | Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. <i>American Heart Journal</i> , 2021, 235, 132-139. | 1.2 | 3 |
| 388 | Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 224-227. | 0.7 | 2 |
| 389 | Treatment Strategies in Non-ST-Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidence-Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. <i>Journal of Interventional Cardiology</i> , 2008, 21, 283-299. | 0.5 | 2 |
| 390 | Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 84-99. | 0.4 | 2 |
| 391 | Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1461-1463. | 1.2 | 2 |
| 392 | Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. <i>American Heart Journal</i> , 2013, 166, 466-473.e1. | 1.2 | 2 |
| 393 | The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 526-532. | 1.0 | 2 |
| 394 | Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 129-138. | 1.0 | 2 |
| 395 | Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Cardiology in Review</i> , 2016, 24, 170-176. | 0.6 | 2 |
| 396 | Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. <i>International Journal of Stroke</i> , 2016, 11, 950-967. | 2.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 397 | Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 214-220. | 1.4 | 2 |
| 398 | Clinical benefits of evolocumab appear less than hoped â€œ Authors' reply. <i>Lancet, The</i> , 2018, 391, 934-935. | 6.3 | 2 |
| 399 | Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. <i>International Journal of Cardiology</i> , 2020, 317, 159-166. | 0.8 | 2 |
| 400 | Comment on: â€œDirect Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilanceâ€• <i>Drug Safety</i> , 2021, 44, 503-504. | 1.4 | 2 |
| 401 | Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. <i>Global Cardiology Science & Practice</i> , 2020, 2020, e202039. | 0.3 | 2 |
| 402 | Relationship of diabetes, heart failure, and Nâ€œterminal proâ€œBâ€œtype natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. <i>ESC Heart Failure</i> , 2022, , . | 1.4 | 2 |
| 403 | Neural Networks, Logistic Regression, and Calibration: A Reply. <i>Medical Decision Making</i> , 1998, 18, 444-445. | 1.2 | 1 |
| 404 | Improving antithrombotic treatment in patients after myocardial infarction. <i>Lancet, The</i> , 2003, 362, 757. | 6.3 | 1 |
| 405 | Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. <i>Future Cardiology</i> , 2006, 2, 85-91. | 0.5 | 1 |
| 406 | Glycoprotein IIb-IIIa Inhibitors in the Emergency Department for Patients with Non-ST-Elevation Acute Coronary Syndromes: Principles and Practices. <i>Journal of Emergency Medicine</i> , 2009, 36, 162-170. | 0.3 | 1 |
| 407 | Day 1 care in patients with non-ST-segment elevation myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2010, 11, 41-51. | 0.3 | 1 |
| 408 | Perspectives on the 2009 Focused Updates on the Management of ST-Segment Elevation Myocardial Infarction and Percutaneous Intervention. <i>Critical Pathways in Cardiology</i> , 2010, 9, 126-133. | 0.2 | 1 |
| 409 | Management of Nonâ€œST-Segment Elevation Acute Coronary Syndrome. <i>Critical Pathways in Cardiology</i> , 2012, 11, 62-73. | 0.2 | 1 |
| 410 | Letter from the Editor. <i>Cardiology and Therapy</i> , 2012, 1, 1. | 1.1 | 1 |
| 411 | Emerging antithrombotic drugs for acute coronary syndrome. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 307-318. | 1.0 | 1 |
| 412 | Cardiac Sarcoidosis: Case Report, Workup, and Review of the Literature. <i>Cardiology and Therapy</i> , 2013, 2, 181-197. | 1.1 | 1 |
| 413 | Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 199-210. | 1.0 | 1 |
| 414 | Response to Letter Regarding Article, â€œSustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Nonâ€œST-Segment Elevation Acute Coronary Syndromesâ€• <i>Circulation</i> , 2013, 127, e634. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Do Diabetic Patients with Acute Coronary Syndromes Have a Higher Threshold for Ischemic Pain?. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 103, 183-91. | 0.3 | 1 |
| 416 | Target-Specific Oral Anticoagulants: Practice Issues for the Clinician. <i>Hospital Practice</i> (1995), 2014, 42, 48-61. | 0.5 | 1 |
| 417 | Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants. <i>European Heart Journal</i> , 2014, 35, 207-208. | 1.0 | 1 |
| 418 | Influence of proven oral therapies in the very old with acute coronary syndromes: A 15year experience. <i>International Journal of Cardiology</i> , 2015, 198, 213-215. | 0.8 | 1 |
| 419 | Reply. <i>Journal of the American College of Cardiology</i> , 2016, 67, 3025-3026. | 1.2 | 1 |
| 420 | Reply. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1200. | 1.2 | 1 |
| 421 | Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1013-1019. | 0.9 | 1 |
| 422 | Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020, 75, 835-837. | 1.2 | 1 |
| 423 | Reply. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3232-3233. | 1.2 | 1 |
| 424 | A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. <i>Journal of the American College of Cardiology</i> , 2021, 78, 634-636. | 1.2 | 1 |
| 425 | Letter to the editor re: "serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review". <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 281-282. | 1.3 | 1 |
| 426 | Abstract 16708: Increasing Age and the Benefit From Higher-intensity Lipid Lowering With Ezetimibe/Simvastatin vs. Simvastatin Alone: Results From the IMPROVE-IT Trial. <i>Circulation</i> , 2015, 132, . | 1.6 | 1 |
| 427 | Importance of dose selection in novel oral anticoagulants for atrial fibrillation. <i>Archivos De Cardiologia De Mexico</i> , 2012, 82, 308-311. | 0.1 | 1 |
| 428 | Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. <i>Advances in Therapy</i> , 2022, 39, 1832-1843. | 1.3 | 1 |
| 429 | Prognostic stratification of the patient after myocardial infarction in the thrombolytic era. <i>ACC Current Journal Review</i> , 1995, 4, 36-39. | 0.1 | 0 |
| 430 | Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 1997, 4, 321-323. | 1.0 | 0 |
| 431 | Baseline troponin in acute coronary syndromes managed invasively. <i>American Journal of Medicine</i> , 2004, 117, 963-965. | 0.6 | 0 |
| 432 | Non ST-Elevation Acute Coronary Syndromes. , 2007, , 221-245. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 433 | ED to catheterization laboratory: a roundtable integrating trials with practice. American Journal of Emergency Medicine, 2011, 29, 1203-1216. | 0.7 | 0 |
| 434 | Adjunctive pharmacologic therapy in percutaneous coronary intervention. Coronary Artery Disease, 2011, 22, 100-112. | 0.3 | 0 |
| 435 | Adjunctive pharmacologic therapy in percutaneous coronary intervention. Coronary Artery Disease, 2011, 22, 113-121. | 0.3 | 0 |
| 436 | Relationships Among Race, Bleeding, and Mortality in Coronary Reperfusion. Circulation, 2012, 125, 1715-1717. | 1.6 | 0 |
| 437 | Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. Journal of Thrombosis and Thrombolysis, 2013, 36, 115-130. | 1.0 | 0 |
| 438 | Non-ST-Segment Elevation Acute Coronary Syndromes. , 2013, , 153-177. | | 0 |
| 439 | Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?. Future Cardiology, 2014, 10, 153-155. | 0.5 | 0 |
| 440 | Editors' Picks for 2014 and a Look into the Future. Cardiology and Therapy, 2015, 4, 1-3. | 1.1 | 0 |
| 441 | Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation, 2016, 133, e463. | 1.6 | 0 |
| 442 | Overview of the non-vitamin K oral anticoagulants for atrial fibrillation. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 77-79. | 1.0 | 0 |
| 443 | Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq1 1 0.784314 rgBTd/Overlo | | |
| 444 | Reply. Journal of the American College of Cardiology, 2019, 74, 2436-2437. | 1.2 | 0 |
| 445 | Cardiology and Therapy: A Summary of 2018 and Key Areas of Emerging Research in 2019. Cardiology and Therapy, 2019, 8, 1-3. | 1.1 | 0 |
| 446 | Correctly understanding the diabetes data in FOURIER. Diabetes, Obesity and Metabolism, 2019, 21, 2342-2343. | 2.2 | 0 |
| 447 | Interindividual and Intraindividual Responses to PCSK9 Inhibition"Reply. JAMA Cardiology, 2019, 4, 600. | 3.0 | 0 |
| 448 | Association of APOE genotype and lipid lowering with cognitive function in a randomized placebo-controlled trial of Evolocumab. Alzheimer's and Dementia, 2020, 16, e047188. | 0.4 | 0 |
| 449 | Myocardial Infarction and Evolocumab"Reply. JAMA Cardiology, 2021, 6, 1222. | 3.0 | 0 |
| 450 | Assessment of the Change of a Continuous Variable as a Function of its Initial Value"Reply. JAMA Cardiology, 2021, 6, 1342. | 3.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 451 | Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. <i>Fundamental and Clinical Cardiology</i> , 2009, , 19-36. | 0.0 | 0 |
| 452 | Novel Oral Antiplatelet Agents. <i>European Cardiology Review</i> , 2011, 7, 294. | 0.7 | 0 |
| 453 | Abstract 14997: Icosapent Ethyl Reduces Ischemic Events in Patients With Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2020, 142, . | 1.6 | 0 |
| 454 | Abstract 15091: Significant Reductions in Both Adjudicated and Investigator-Reported Ischemic Events in REDUCE-IT. <i>Circulation</i> , 2020, 142, . | 1.6 | 0 |
| 455 | Abstract 13200: Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T <i>Circulation</i> , 2020, 142, . | 1.6 | 0 |
| 456 | Reply. <i>Journal of the American College of Cardiology</i> , 2022, 79, e153. | 1.2 | 0 |